HUP0301590A2 - Nem-peptiddel szubsztituált spirobenzoazepinek, mint vazopresszin antagonisták, ezeket tartalmazó gyógyszerkészítmények és elżállításuk - Google Patents
Nem-peptiddel szubsztituált spirobenzoazepinek, mint vazopresszin antagonisták, ezeket tartalmazó gyógyszerkészítmények és elżállításukInfo
- Publication number
- HUP0301590A2 HUP0301590A2 HU0301590A HUP0301590A HUP0301590A2 HU P0301590 A2 HUP0301590 A2 HU P0301590A2 HU 0301590 A HU0301590 A HU 0301590A HU P0301590 A HUP0301590 A HU P0301590A HU P0301590 A2 HUP0301590 A2 HU P0301590A2
- Authority
- HU
- Hungary
- Prior art keywords
- optionally substituted
- independently
- aryl
- substituted alkyl
- group
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 229940116211 Vasopressin antagonist Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003038 vasopressin antagonist Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- -1 amino- Chemical class 0.000 abstract 4
- 206010019280 Heart failures Diseases 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 206010003225 Arteriospasm coronary Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010048962 Brain oedema Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010016807 Fluid retention Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000027601 Inner ear disease Diseases 0.000 abstract 1
- 208000001738 Nervous System Trauma Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 102000004136 Vasopressin Receptors Human genes 0.000 abstract 1
- 108090000643 Vasopressin Receptors Proteins 0.000 abstract 1
- 206010047163 Vasospasm Diseases 0.000 abstract 1
- 125000005035 acylthio group Chemical group 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 abstract 1
- 125000005362 aryl sulfone group Chemical group 0.000 abstract 1
- 125000005361 aryl sulfoxide group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 abstract 1
- 208000006752 brain edema Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 208000028412 nervous system injury Diseases 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 239000002536 vasopressin receptor antagonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A találmány (I) általános képletű a nem-peptid-szubsztituáltbenzodiazepinekre vonatkozik, ahol R1 jelentése egy-három egymástólfüggetlen hidrogénatom, halogénatom, amino-, szubsztituált amino-,hidroxil-, alkoxi- adott esetben szubsztituált fenil-, akil-tio-,aril-tio-, alkil-szulfoxid-, aril-szulfoxid-, alkil-szulfon- vagyaril-szulfon-csoport; -R2-R3- jelentése ahol R' jelentése adottesetben szubsztituált alkil-, adott esetben szubsztituált fenil-,adott esetben szubsztituált heteroarilcsoport és -Bp-G-Eq-W, ahol (a)B jelentése (CH2)m, NH vagy O; (b) G jelentése aril-, szubsztituáltaril- vagy adott esetben szubsztituált heteroarilcsoport; (c) Ejelentése O, S, NH, (CH2);N(R<)CO vagy (CH2); CONR<, ahol R< jelentésehidrogénatom vagy adott esetben szubsztituált alkilcsoport; (d) Wjelentése egy-három egymástól független hidrogénatom, adott esetben aszubsztituált alkil-, adott esetben szubsztituált amino-, alkil-tio-fenil-, alkil-szulfoxid-fenil-, adott esetben szubsztituált aril- vagyadott esetben szubsztituált heteroaril-csoport; (e) p értéke egymástólfüggetlenül 0 vagy 1; (f) q értéke egymástól függetlenül 0 vagy 1; (g)m értéke egymástól függetlenül 1, 2 vagy 3; és (h) i értéke egymástólfüggetlenül 0, 1, 2 vagy 3; R4 jelentése egy vagy két egymástólfüggetlen hidrogénatom, adott esetben szubsztituált alkil- vagy adottesetben szubsztituált fenilcsoport; R5 jelentése hidrogénatom, adottestben szubsztituált alkil-, aldehid-, karboxil-, alkoxi-karbonil-,szubsztituált alkoxi-karbonil-, -(CH2)kNZ1Z2 vagy -CONZ1Z2 csoport,ahol k értéke 1-4 közötti egész szám, és Z1 és Z2 egymástólfüggetlenül hidrogénatom, adott esetben szubsztituált alkil-, adottesetben szubsztituált heterociklusos, adott esetben szubsztituáltamino-karbonil-csoport, vagy N, Z1 és Z2 együtt adott esetbenszubsztituált heterociklusos vagy adott esetben szubsztituáltheteroarilcsoportot képez; a jelentése egyszeres vagy kettős kötés; Ajelentése aril-, naftil- vagy heteroarrilcsoport; X jelentése CH, CH2,CHOH vagy C=O; és n értéke 1, 2 vagy 3 -, amelyek vazopresszinreceptor antagonisták vazopresszin receptor hatással kapcsolatosállapotok kezelésére, pl. megnövekedett érellenállás,szívelégtelenség. Az (I) általános képletű vegyületeket tartalmazógyógyászati készítmények alkalmasak a következő betegségek kezelésére:belső fülrendellenesség, magas vérnyomás, szívszélhűdés,szívelégtelenség, koszorúérgörcs, szív ischémia, májzsugor,veseérgörcs, veseelégtelenség, agyi ödéma és iszchémia, szélütés,trombózis, vízretenció, aggresszió, kényszerképzetes rendellenesség,fájdalmas menstruáció, veseszindróma és központi idegrendszerisérülés. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21622000P | 2000-07-05 | 2000-07-05 | |
| PCT/US2001/021080 WO2002002531A1 (en) | 2000-07-05 | 2001-07-02 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0301590A2 true HUP0301590A2 (hu) | 2003-09-29 |
| HUP0301590A3 HUP0301590A3 (en) | 2005-01-28 |
Family
ID=22806231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0301590A HUP0301590A3 (en) | 2000-07-05 | 2001-07-02 | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists, pharmaceutical compositions containing them and their preparation |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US7001898B2 (hu) |
| EP (1) | EP1307430B1 (hu) |
| JP (1) | JP4916639B2 (hu) |
| CN (1) | CN1449386B (hu) |
| AT (1) | ATE305454T1 (hu) |
| AU (2) | AU7178001A (hu) |
| BR (1) | BR0112372A (hu) |
| CA (1) | CA2413945C (hu) |
| DE (1) | DE60113696T2 (hu) |
| DK (1) | DK1307430T3 (hu) |
| ES (1) | ES2250432T3 (hu) |
| HU (1) | HUP0301590A3 (hu) |
| IL (2) | IL153710A0 (hu) |
| MX (1) | MXPA03000135A (hu) |
| MY (1) | MY135101A (hu) |
| NO (1) | NO324499B1 (hu) |
| NZ (1) | NZ523450A (hu) |
| TW (1) | TWI316057B (hu) |
| WO (1) | WO2002002531A1 (hu) |
| ZA (1) | ZA200300972B (hu) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE305454T1 (de) * | 2000-07-05 | 2005-10-15 | Ortho Mcneil Pharm Inc | Nichtpeptidische substituierte spirobenzoazepine als vasopressin antagonisten |
| EP1364968A1 (en) * | 2002-05-23 | 2003-11-26 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 1 (AVPR1) |
| CA2529649C (en) * | 2003-06-17 | 2012-01-31 | Janssen Pharmaceutica N.V. | Substituted spirobenzazepines |
| JP2007516177A (ja) * | 2003-06-17 | 2007-06-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法 |
| CA2637838A1 (en) * | 2006-01-20 | 2007-07-26 | Janssen Pharmaceutica N.V. | Novel solid forms of (4r)-1-¬4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl|-1,2,3,5-tetrahydro-spiro¬4h-1-benzazepine-4,1'-¬2|cyclopentene|-3'-carboxylic acid |
| JP2010504352A (ja) * | 2006-09-22 | 2010-02-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | バソプレッシン拮抗薬としてのスピロベンズアゼピン類 |
| CN101541806A (zh) * | 2006-09-22 | 2009-09-23 | 詹森药业有限公司 | 用作血管升压素拮抗剂的螺环苯并氮杂 |
| AR066834A1 (es) * | 2007-06-06 | 2009-09-16 | Janssen Pharmaceutica Nv | Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central. |
| CN102176908A (zh) * | 2008-10-10 | 2011-09-07 | 詹森药业有限公司 | 包括血管紧张素受体阻滞剂和加压素受体拮抗剂的联合疗法 |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| CN116472271A (zh) * | 2020-11-26 | 2023-07-21 | 上海济煜医药科技有限公司 | 新型苯并氮杂卓螺环衍生物 |
| CN112939864B (zh) * | 2021-01-29 | 2022-05-06 | 中国医科大学 | 螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617302A (en) * | 1984-10-15 | 1986-10-14 | Eli Lilly And Company | Inotropic agents |
| ZA882080B (en) * | 1987-03-27 | 1989-04-26 | Schering Corp | Substituted benzazepines,their preparation and pharmaceutical compositions containing them |
| US5258510A (en) | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
| ES2089033T3 (es) * | 1989-10-20 | 1996-10-01 | Otsuka Pharma Co Ltd | Compuestos benzoheterociclicos. |
| US5985869A (en) | 1989-10-20 | 1999-11-16 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
| CA2066104C (en) * | 1991-04-19 | 2003-05-27 | Hidenori Ogawa | Benzazepine derivatives as vasopressin antagonists |
| FR2708605A1 (fr) | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5663431A (en) | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5686624A (en) | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5849780A (en) | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| CA2143117A1 (en) * | 1992-10-07 | 1994-04-14 | Ben E. Evans | Tocolytic oxytocin receptor antagonists |
| US5512563A (en) * | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US5753648A (en) | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5753715A (en) | 1995-06-02 | 1998-05-19 | Ortho Pharmaceutical Corporation | 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents |
| AUPP150098A0 (en) | 1998-01-27 | 1998-02-19 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| AR018818A1 (es) * | 1998-04-03 | 2001-12-12 | Yamano Masaki | Una composicion farmaceutica para la terapia de un edema. |
| ATE305454T1 (de) | 2000-07-05 | 2005-10-15 | Ortho Mcneil Pharm Inc | Nichtpeptidische substituierte spirobenzoazepine als vasopressin antagonisten |
-
2001
- 2001-07-02 AT AT01950821T patent/ATE305454T1/de active
- 2001-07-02 EP EP01950821A patent/EP1307430B1/en not_active Expired - Lifetime
- 2001-07-02 AU AU7178001A patent/AU7178001A/xx active Pending
- 2001-07-02 BR BR0112372-6A patent/BR0112372A/pt not_active Application Discontinuation
- 2001-07-02 IL IL15371001A patent/IL153710A0/xx unknown
- 2001-07-02 US US09/897,206 patent/US7001898B2/en not_active Expired - Lifetime
- 2001-07-02 CN CN018149278A patent/CN1449386B/zh not_active Expired - Lifetime
- 2001-07-02 WO PCT/US2001/021080 patent/WO2002002531A1/en active IP Right Grant
- 2001-07-02 HU HU0301590A patent/HUP0301590A3/hu unknown
- 2001-07-02 DK DK01950821T patent/DK1307430T3/da active
- 2001-07-02 ES ES01950821T patent/ES2250432T3/es not_active Expired - Lifetime
- 2001-07-02 AU AU2001271780A patent/AU2001271780B2/en not_active Expired
- 2001-07-02 MX MXPA03000135A patent/MXPA03000135A/es active IP Right Grant
- 2001-07-02 DE DE60113696T patent/DE60113696T2/de not_active Expired - Lifetime
- 2001-07-02 CA CA2413945A patent/CA2413945C/en not_active Expired - Lifetime
- 2001-07-02 JP JP2002507788A patent/JP4916639B2/ja not_active Expired - Lifetime
- 2001-07-02 NZ NZ523450A patent/NZ523450A/en not_active IP Right Cessation
- 2001-07-05 TW TW090116416A patent/TWI316057B/zh not_active IP Right Cessation
- 2001-07-05 MY MYPI20013213A patent/MY135101A/en unknown
-
2002
- 2002-12-27 IL IL153710A patent/IL153710A/en active IP Right Grant
-
2003
- 2003-01-03 NO NO20030028A patent/NO324499B1/no not_active IP Right Cessation
- 2003-02-04 ZA ZA200300972A patent/ZA200300972B/en unknown
- 2003-05-19 US US10/440,914 patent/US7238687B2/en not_active Expired - Lifetime
-
2006
- 2006-10-16 US US11/549,678 patent/US7691844B2/en not_active Expired - Lifetime
- 2006-11-29 US US11/564,471 patent/US7365062B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0301590A2 (hu) | Nem-peptiddel szubsztituált spirobenzoazepinek, mint vazopresszin antagonisták, ezeket tartalmazó gyógyszerkészítmények és elżállításuk | |
| RU2395500C2 (ru) | 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| EA200300428A1 (ru) | Антагонисты метаботропных рецепторов глутамата | |
| EA200200716A1 (ru) | Арилконденсированные азаполициклические соединения | |
| MA28270A1 (fr) | Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2 | |
| NO20034523D0 (no) | Pyrazolderivater for behandling av HIV | |
| DK1353911T3 (da) | Antivirale midler | |
| AP1635A (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease. | |
| MXPA03011244A (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6. | |
| MEP9509A (en) | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof | |
| AR038864A1 (es) | Inhibidores pirimidina y piridina biciclicos de la p38 quinasa | |
| MY116542A (en) | New inhibitors of platelet aggregation. | |
| AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
| BR9917086A (pt) | Benzodiazepinas tricìclicas como antagonistas dosreceptores de vasopressina | |
| EA200401114A3 (ru) | Замещённые гидроксиэтиламины | |
| EA200301203A1 (ru) | Новые соединения и композиции как ингибиторы катепсина | |
| EA200000996A1 (ru) | Конденсированные с арилом азаполициклические соединения | |
| ATE485822T1 (de) | Phenylaminopyridine und phenylaminopyrazine | |
| ATE384714T1 (de) | Pyrazolderivate | |
| SE9904177D0 (sv) | Novel compounds | |
| CY1106576T1 (el) | Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας | |
| FR2687677B1 (fr) | Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant. | |
| BRPI0514907A (pt) | derivados do pirrol [3,2 -c] piridina e processos para a sua preparação | |
| DE60319254D1 (de) | Pyrazolamide zur behandlung von hiv-infektionen | |
| EA201300599A1 (ru) | Замещенные гидрированные тиено-пирроло[3,2-с]пиридины, лиганды, фармацевтическая композиция и способ их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |